# GR270773 In The Treatment Of Suspected Or Confirmed Gram-Negative Severe Sepsis In Adults

> **NCT00089986** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 1415 (actual)

## Conditions studied

- Sepsis

## Interventions

- **DRUG:** Intravenous GR270773- Phospholipid Emulsion
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT00089986
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-09-01
- **Primary completion:** 2007-04-01
- **Final completion:** 2007-04-15
- **Target enrollment:** 1415 (ACTUAL)
- **Last updated:** 2017-08-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00089986

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00089986, "GR270773 In The Treatment Of Suspected Or Confirmed Gram-Negative Severe Sepsis In Adults". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00089986. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*